Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16628169rdf:typepubmed:Citationlld:pubmed
pubmed-article:16628169lifeskim:mentionsumls-concept:C0019994lld:lifeskim
pubmed-article:16628169lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:16628169lifeskim:mentionsumls-concept:C0598391lld:lifeskim
pubmed-article:16628169pubmed:issue6lld:pubmed
pubmed-article:16628169pubmed:dateCreated2006-4-21lld:pubmed
pubmed-article:16628169pubmed:abstractTextThis article evaluates satisfaction with enzyme replacement therapy (ERT) at home and at hospital in adult patients with Fabry and Gaucher diseases. A questionnaire was developed and sent to 34 patients with Fabry disease who were receiving ERT with agalsidase alfa (Replagal) and to 49 patients with type I Gaucher disease who were receiving ERT with glucocerebrosidase (Cerezyme). Of the 45 returned questionnaires, 20 were from patients with Fabry disease and 25 from patients with Gaucher disease. Hospital treatment visits were reported as stressful by 18 patients (40%), whereas only 4 (9%) patients reported that home therapy was stressful. Both groups of patients adjusted well to receiving home-based therapy. Nearly all of the patients with Fabry disease (19 patients, 95%) and Gaucher disease (21 patients, 84%) preferred home-based therapy. Treatment in the home was reported as more comfortable, less stressful, more effective and had less impact on family life. Only 4 (9%) patients chose to continue receiving infusions in hospital. The majority of patients with Fabry disease and Gaucher disease found home-based therapy to be more convenient and less stressful than hospital-based therapy.lld:pubmed
pubmed-article:16628169pubmed:languageenglld:pubmed
pubmed-article:16628169pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16628169pubmed:citationSubsetNlld:pubmed
pubmed-article:16628169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16628169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16628169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16628169pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16628169pubmed:statusMEDLINElld:pubmed
pubmed-article:16628169pubmed:issn0966-0461lld:pubmed
pubmed-article:16628169pubmed:authorpubmed-author:MehtaAAlld:pubmed
pubmed-article:16628169pubmed:authorpubmed-author:HughesDDlld:pubmed
pubmed-article:16628169pubmed:authorpubmed-author:RichfieldLLlld:pubmed
pubmed-article:16628169pubmed:authorpubmed-author:GoodwinSSlld:pubmed
pubmed-article:16628169pubmed:authorpubmed-author:MilliganAAlld:pubmed
pubmed-article:16628169pubmed:issnTypePrintlld:pubmed
pubmed-article:16628169pubmed:volume15lld:pubmed
pubmed-article:16628169pubmed:ownerNLMlld:pubmed
pubmed-article:16628169pubmed:authorsCompleteYlld:pubmed
pubmed-article:16628169pubmed:pagination330-3lld:pubmed
pubmed-article:16628169pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:meshHeadingpubmed-meshheading:16628169...lld:pubmed
pubmed-article:16628169pubmed:articleTitleIntravenous enzyme replacement therapy: better in home or hospital?lld:pubmed
pubmed-article:16628169pubmed:affiliationLysosomal Storage Disorders Unit, Royal Free Hospital, London, UK.lld:pubmed
pubmed-article:16628169pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16628169pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16628169pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16628169lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16628169lld:pubmed